BioApplications Inc.

BioApp was established in 2011 based on POSTECH's plant biotechnology. It has achieved significant milestones, being the first to accomplish various achievements in both Korea and globally. Notably, the HERBAVAC™ CSF Green Marker vaccine, the world's inaugural plant-based classical swine fever vaccine, has been approved. BioApp aims to contribute to eliminating classical swine fever by achieving CSF-free status in Korea and entering the global market. Beyond animal vaccines, BioApp is engaged in developing vaccines for COVID-19, Zika, and dementia prevention. The company strives to establish a green vaccine production system to ensure swift delivery of secure and efficient vaccines, enhancing vaccine self-sufficiency to safeguard public health from severe infectious diseases.